Caribou Biosciences, Inc.
CRBU
$1.86
$0.105.68%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.30M | 9.12M | 9.92M | 9.99M | 11.48M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.30M | 9.12M | 9.92M | 9.99M | 11.48M |
| Cost of Revenue | 34.12M | 34.54M | 35.24M | 35.11M | 36.53M |
| Gross Profit | -24.82M | -25.42M | -25.32M | -25.12M | -25.05M |
| SG&A Expenses | 39.82M | 40.47M | 41.55M | 46.46M | 45.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 155.31M | 163.98M | 172.85M | 176.01M | 176.66M |
| Operating Income | -146.02M | -154.85M | -162.93M | -166.02M | -165.18M |
| Income Before Tax | -157.14M | -164.27M | -147.87M | -149.11M | -147.93M |
| Income Tax Expenses | -9.00K | -9.00K | -9.00K | -9.00K | 193.00K |
| Earnings from Continuing Operations | -157.13 | -164.26 | -147.86 | -149.11 | -148.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -157.13M | -164.26M | -147.86M | -149.11M | -148.12M |
| EBIT | -146.02M | -154.85M | -162.93M | -166.02M | -165.18M |
| EBITDA | -141.87M | -150.16M | -158.55M | -162.09M | -161.70M |
| EPS Basic | -1.70 | -1.79 | -1.62 | -1.65 | -1.65 |
| Normalized Basic EPS | -0.98 | -1.03 | -1.01 | -1.03 | -1.03 |
| EPS Diluted | -1.70 | -1.79 | -1.62 | -1.65 | -1.65 |
| Normalized Diluted EPS | -0.98 | -1.03 | -1.01 | -1.03 | -1.03 |
| Average Basic Shares Outstanding | 370.16M | 367.33M | 364.64M | 361.26M | 358.53M |
| Average Diluted Shares Outstanding | 370.16M | 367.33M | 364.64M | 361.26M | 358.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |